Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

The Danish company reported DKK 78.1B ($11.9B) in revenue for Q1, implying ~19% YoY growth but signaling a ~9% decline compared to the preceding quarter as Wegovy sales plunged ~13% QoQ to DKK 17 ...

Novo Nordisk (NVO) said on Monday that it will cease its partnership with Hims & Hers Health (NYSE:HIMS), ending the direct access to Wegovy, its weight loss drug, through NovoCare Pharmacy. In ...

Novo Nordisk said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in a move that coincides with a deadline for halting sales of cheaper ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down. The Danish company is citing a steep decline in the company’s share price.